FDA Launches Rare Disease Framework Initiative: What It Could Mean for Our Community Highlights

• The FDA launched the Rare Disease Framework Initiative on October 14, 2026.
• About 30 million Americans, roughly one in ten, live with a rare disease.
• Only about 5% of recognized rare diseases have an FDA-approved treatment.
• The FDA plans to bring the patient voice in early and at set milestones.
• Patients and caregivers are invited to share input, starting with an October 28 public meeting.

If you’re living with a rare disease, or caring for someone who is, you know how frustrating it can be to wait for treatments that seem to take forever to arrive. That’s why a new announcement from the U.S. Food and Drug Administration caught our attention, and we wanted to share it with our community.

On October 14, 2026, the FDA launched the Rare Disease Framework Initiative, an effort to rethink how treatments for rare diseases are developed and reviewed. As a patient-founded, patient-led community, we were especially glad to see patients placed at the center of this work.

The scale of the need

According to the FDA’s white paper, about 30 million Americans, roughly one in ten, live with a rare disease. In the U.S., a disease is considered rare when it affects fewer than 200,000 people, and many affect far fewer. Yet only about 5% of recognized rare diseases have an FDA-approved treatment. The FDA also notes that many patients end up using treatments approved for other conditions because nothing has been proven for their specific disease.

Why rare diseases are harder to study

The white paper is honest about the challenges. Patient groups are small and often spread out geographically, which makes clinical trial enrollment slow. Information about how a disease naturally progresses is often limited, and the tools commonly used in larger studies may simply not be available. The FDA says rare diseases need an approach based on the evidence that can realistically be gathered, the type of treatment, and what patients need, and that this approach should be used consistently across its review teams.

What the FDA is committing to

The FDA says the new framework will:

• Bring more clarity, consistency, and predictability to decisions for patients, advocates, researchers, and drug developers.
• Include the patient voice early and at clearly defined milestones, so reviewers understand disease burden, what risks and benefits matter most to patients, and what progress looks like to them.
• Draw more on outside disease experts.
• Build shared resources and training for FDA reviewers.
• Use risk-based approaches to manufacturing reviews and inspections to support earlier patient access.
• Champion cutting-edge science, new trial designs, and innovative statistical methods.

Throughout, the FDA stresses that its standards for safety and effectiveness will not change.

Why this matters to us

The FDA’s announcement and white paper don’t mention ocular melanoma specifically. But the challenges they describe will sound familiar to anyone in a rare cancer community: small patient numbers, limited options, and the hope that our experiences will truly shape the process. We were also encouraged to see that the FDA’s Oncology Center of Excellence will be involved where its work overlaps.

Your voice is invited

This is where our community comes in. The FDA plans several ways to gather input:

• A public meeting on October 28 at the FDA’s White Oak campus, facilitated by the Reagan-Udall Foundation, where comments can be submitted on the record.
• A Federal Register Request for Information inviting written input from patients, caregivers, and the public.
• Roundtables that include patient and disease advocacy organizations.

The FDA says the final framework may include new or revised regulations and guidance, along with training for its staff, but those details are still being shaped. That makes this the right moment to speak up.

Read the full announcement here: FDA Launches the Rare Disease Framework Initiative

Learn more and find participation details on the FDA’s Rare Disease Framework page.

We’d love to hear from you. What would you want the FDA to understand about living with ocular melanoma? Share your thoughts with us, and connect with others in our community who know this journey firsthand. Together, our voices are stronger.